innovita.com.cnCrawled Nov 9, 2026
The company’s POCT rapid diagnostic services include digestive tract virus testing.
The company provides hepatitis virus testing as part of its POCT rapid diagnostic services.
北京英诺特生物技术股份有限公司 offers reproductive health testing through its POCT rapid diagnostic solutions.
The page provides market trends and official announcements for 北京英诺特生物技术股份有限公司’s POCT rapid diagnostic reagents.
The company invites applications for roles in its POCT rapid diagnostic reagent development, production, and sales operations.
Beijing Innotest Biotech focuses on developing, producing, and selling POCT rapid diagnostic reagents for respiratory, gastrointestinal, and prenatal/fertility testing.
北京英诺特生物技术股份有限公司 develops, produces, and sells POCT rapid diagnostic reagents for respiratory, digestive, and reproductive health testing.
Contact information for 北京英诺特生物技术股份有限公司 is available for inquiries about its POCT rapid diagnostic reagents.
The page answers common questions about 北京英诺特生物技术股份有限公司’s POCT rapid diagnostic reagents.
An online map directs users to 北京英诺特生物技术股份有限公司’s locations for POCT rapid diagnostic testing.
The company lists service locations for its POCT rapid diagnostic testing in respiratory, digestive, and reproductive health.
北京英诺特生物技术股份有限公司 specializes in developing, producing, and selling POCT rapid diagnostic reagents, focusing on testing solutions.
Innovita obtains NMPA approval in China for Quanterix’s ultra-sensitive blood-based biomarker testing platform. The technology supports earlier detection of Alzheimer’s disease through blood analysis. Regulatory clearance expands access to advanced diagnostics in China’s healthcare system.
Oct 2026Bioanalysis ZoneNews article
Quanterix and Innovita advance their strategic partnership to develop next-generation diagnostic tools. The collaboration focuses on integrating Quanterix’s ultra-sensitive protein detection technology with Innovita’s platform. Early milestones include joint research on biomarkers for neurological disorders, aiming to improve early disease detection.
Oct 2026innovitaivd.comNews article
China’s National Medical Products Administration (NMPA) approves Quanterix and Innovita’s SIMOA instruments and blood-based neurology tests. The clearance enables detection of Alzheimer’s and other neurodegenerative biomarkers in blood samples, expanding access to early diagnostic tools in China. Both companies specialize in ultrasensitive immunoassay technologies for neurological disease research.
Oct 2026Clinical Lab ProductsNews article
Quanterix secures broader US rights to Alzpath’s p-tau 217 antibody technology for Alzheimer’s diagnostics. Its Chinese partner, Innovita, gains regulatory approval for neurology markers and related instruments. The deal expands Quanterix’s access to Alzpath’s proprietary biomarker tools.
Oct 2026genomeweb.comNews article
